Bicara TherapeuticsvsMerck & Company

BCAX and MRK stock compared: price, dividend, valuation and results, from SEC filings.

BCAX

Bicara Therapeutics Inc.

$8.44

Value $553M

-7.46%
BCAX's page

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

Bicara Therapeutics (BCAX) has a market value of $553M and Merck & Company (MRK) $331B. Over the last year, with dividends, BCAX moved -44.4% and MRK +44.8%. Dividend yield: BCAX none, MRK 2.54%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BCAX$553M

    MRK$331B

    MRK is 598 times BCAX

  • Revenue, 12 months

    BCAX–

    MRK$67.4B

  • Net income, 12 months

    BCAX-$220M

    MRK$2.5B

  • Operating margin

    BCAX–

    MRK–

  • ROIC

    BCAX-30.6%

    MRK3.9%

    34.5 points apart

  • P/E

    BCAX–

    MRK134.8

  • Dividend yield

    BCAX0.0%

    MRK2.5%

    2.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BCAX-44.4%

MRK+44.8%

50100150DecFebAprJunAugOct
Returns by period
PeriodBCAXWith dividendsMRKWith dividends
1 year since November 19, 2025-44.4%Price -44.4%+44.8%Price +40.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BCAXBicara TherapeuticsMRKMerck & Company

Valuation

BCAXMRK
Valuation
Price$8.44$133.72
Market value$553M$331B
Enterprise value (EV)$110M$375B
P/E–134.8
P/E, 5-year median–14.8
P/B1.47.4
EV/EBIT–78.7
Free cash flow yield–4.5%

Results and growth

BCAXMRK
Results and growth
Revenue, 12 months–$67.4B
Net income, 12 months-$220M$2.5B
Free cash flow, 12 months-$163M$14.7B
Earnings per share, 12 months-$3.47$0.98
Revenue growth, year on year–1.3%
Revenue growth a year, past–+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

BCAXMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin––
Net margin–3.6%
ROIC-30.6%3.9%
ROE-50.1%5.2%

Balance sheet

BCAXMRK
Balance sheet
Cash$442M$9.7B
Total debt$880.0K$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

BCAXMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BCAX or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Bicara Therapeutics or Merck & Company?

By market value, Merck & Company ($331B) is about 598.3 times Bicara Therapeutics ($553M), at today's prices.

How did BCAX and MRK stock do over the last 1 years?

Since November 19, 2025, BCAX's price moved -44.4% and MRK's +40.7%. With dividends: BCAX -44.4% (-44.4% a year), MRK +44.8% (+44.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, BCAX or MRK?

The dividend yield at today's price is none for Bicara Therapeutics and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which is the better investment, Bicara Therapeutics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.